The latest update is out from Assertio Therapeutics ( (ASRT) ).
In an eventful third quarter, Assertio Holdings reported net product sales of $28.7 million, with Rolvedon delivering stable sales amid pricing pressures. The company saw a gross margin increase to 74% and a reduction in SG&A expenses, while cash reserves remained steady at $88.6 million. Significant board changes included the retirement of Peter Staple and Jeffrey Vacirca, with David Stark joining as a new independent director, bringing extensive legal and acquisition experience from Teva Pharmaceuticals.
See more data about ASRT stock on TipRanks’ Stock Analysis page.